Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Neuroblastomas represent a spectrum of diseases categorized by histological subtypes, age of the patient, and extent of tumor (stage) at diagnosis. In this study we analyzed Ha-ras p21 (protein with molecular weight of 21,000) expression immunohistochemically on 47 primary human neuroblastomas resected at diagnosis. The data demonstrate that the amount of the Ha-ras product correlates with a favorable prognosis (P less than 0.001) and early stages of disease at diagnosis (P less than 0.05). These findings from unmanipulated human neuroblastomas indicate that the Ha-ras gene product (p21) might play a role in the mechanism(s) controlling aggressiveness in this type of tumor in vivo and that the Ha-ras p21 detected by a simple and reproducible immunohistochemical procedure may be of clinical importance in predicting prognosis in patients with this malignancy.
Tanaka
T
T
Department of Pediatrics, National Kure Hospital, Hiroshima, Japan.
Slamon
D J
DJ
Shimoda
H
H
Waki
C
C
Kawaguchi
Y
Y
Tanaka
Y
Y
Ida
N
N
D000008:Abdominal Neoplasms / Q000235:genetics; D000310:Adrenal Gland Neoplasms / Q000235:genetics; D002675:Child, Preschool; D011905:Genes, ras; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008565:Membrane Proteins / Q000032:analysis*; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D016283:Proto-Oncogene Proteins p21(ras); D013899:Thoracic Neoplasms / Q000235:genetics
D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)